Morgan Stanley lowered the firm’s price target on Legend Biotech (LEGN) to $49 from $50 and keeps an Overweight rating on the shares. The firm, which updated estimates following the company’s Q4 report, awaits additional data from the CARTITUDE-5 study and the earlier-stage in vivo pipeline this year.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LEGN:
- Legend Biotech price target lowered to $62 from $66 at RBC Capital
- Legend Biotech Posts 2025 CARVYKTI Profitability and Tops 10,000 Patients Treated
- Legend Biotech reports Q4 adjusted EPS 1c vs. (15c) last year
- Legend Biotech sees cash runway beyond 2026
- Legend Biotech selloff brings favorable risk/reward, says Deutsche Bank